Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

Love1010 Sep. 14 at 5:44 PM

$NNVC to all new longs: you are buying air. And it will go to zero. Enjoy.

0 · Reply

Love1010 Sep. 13 at 1:13 PM

$NNVC where did all these new pumpers come from? Looks like they need to be schooled!

0 · Reply

CameoBrien Sep. 12 at 8:07 PM

$NNVC not bad

0 · Reply

UltimateTrader_22 Sep. 12 at 7:55 PM

$NNVC Green all day today. Let's close at $1.45+ #Bullish

0 · Reply

CameoBrien Sep. 12 at 7:31 PM

$NNVC nit nat on the ask all day. Let it breathe

0 · Reply

UltimateTrader_22 Sep. 12 at 7:26 PM

$NNVC Let's See Power Hour🔥Swing Opportunity

0 · Reply

Stockprofiler Sep. 12 at 7:14 PM

$NNVC Closing the gap to $2 next week! #bullish

0 · Reply

CameoBrien Sep. 12 at 7:05 PM

$NNVC eod push

0 · Reply

PrnceMichael Sep. 12 at 6:53 PM

$NNVC $1.45's going now! For the last half of the year @NNVC_Inc is trading consistently higher trending and Experts predict this could breakout at any moment. #tightchannel #lowFloat #FDA @NYSE

0 · Reply

StockWorldz Sep. 12 at 6:42 PM

$NNVC 1.45's green heading into power hour!

0 · Reply

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 5 days ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Aug 18, 2025, 8:30 AM EDT - 27 days ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Jul 30, 2025, 8:30 AM EDT - 6 weeks ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 23, 2025, 8:30 AM EDT - 7 weeks ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 21, 2025, 6:30 AM EDT - 7 weeks ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 2 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jun 18, 2025, 6:30 AM EDT - 3 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 3 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 3 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 4 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 4 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 4 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 4 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 5 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 6 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 6 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 7 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 7 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 8 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 8 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 8 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 8 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 9 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 10 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 11 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 11 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 11 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

May 8, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

May 6, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

Apr 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

Feb 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Love1010 Sep. 14 at 5:44 PM

$NNVC to all new longs: you are buying air. And it will go to zero. Enjoy.

0 · Reply

Love1010 Sep. 13 at 1:13 PM

$NNVC where did all these new pumpers come from? Looks like they need to be schooled!

0 · Reply

CameoBrien Sep. 12 at 8:07 PM

$NNVC not bad

0 · Reply

UltimateTrader_22 Sep. 12 at 7:55 PM

$NNVC Green all day today. Let's close at $1.45+ #Bullish

0 · Reply

CameoBrien Sep. 12 at 7:31 PM

$NNVC nit nat on the ask all day. Let it breathe

0 · Reply

UltimateTrader_22 Sep. 12 at 7:26 PM

$NNVC Let's See Power Hour🔥Swing Opportunity

0 · Reply

Stockprofiler Sep. 12 at 7:14 PM

$NNVC Closing the gap to $2 next week! #bullish

0 · Reply

CameoBrien Sep. 12 at 7:05 PM

$NNVC eod push

0 · Reply

PrnceMichael Sep. 12 at 6:53 PM

$NNVC $1.45's going now! For the last half of the year @NNVC_Inc is trading consistently higher trending and Experts predict this could breakout at any moment. #tightchannel #lowFloat #FDA @NYSE

0 · Reply

StockWorldz Sep. 12 at 6:42 PM

$NNVC 1.45's green heading into power hour!

0 · Reply

CameoBrien Sep. 12 at 6:12 PM

$NNVC 👉

0 · Reply

PrnceMichael Sep. 12 at 5:50 PM

$NNVC NanoViricide Platform Enables *Oral Drug Delivery -Oral drug delivery of small chemicals, peptides such as the GLP-a obesity drugs which is a huge market right now. Eli Lilly $LLY , Novo Nordisk $NVO prepare to face off in the next obesity drug battleground https://cnb.cx/4nroYGD Could $NNVC be a better candidate?

0 · Reply

StockWorldz Sep. 12 at 5:27 PM

$NNVC

0 · Reply

Stockprofiler Sep. 12 at 5:00 PM

$NNVC – 5 Key Reasons This Antiviral Microcap Deserves a Look https://www.reddit.com/r/StockMarket/comments/1nf3ogt/nnvc_5_key_reasons_this_antiviral_microcap/?share_id=YKD0IE82AECb7CbOLQJrO&utm_content=1&utm_medium=android_app&utm_name=androidcss&utm_source=share&utm_term=20

0 · Reply

Stockprofiler Sep. 12 at 4:53 PM

$NNVC - 5 Key Reasons This Antiviral Microcap Deserves a Look https://www.reddit.com/r/StockMarket/s/Kd5PARxEN8

0 · Reply

PrnceMichael Sep. 12 at 4:23 PM

$NNVC Don't get caught short. #Alert #Newswatch #FDA #Bullish

0 · Reply

UltimateTrader_22 Sep. 12 at 3:59 PM

$NNVC NanoViricides to Present at the Life Science Executive Partnering Congress in Boston on September 17, 2025 NV-387 demonstrated high effectiveness against RSV, Influenza A, and Coronaviruses in animal models Potential market size exceeds $10 billion https://www.stocktitan.net/news/NNVC/retransmission-nano-viricides-to-present-at-the-life-science-55k9fg5gtbyv.html

0 · Reply

CameoBrien Sep. 12 at 3:57 PM

$NNVC bids strong

0 · Reply

UltimateTrader_22 Sep. 12 at 3:37 PM

$NNVC Great chart. Thanks! ----- Next Week will be Lit!!!! NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy.

0 · Reply

St0ckman691 Sep. 12 at 3:35 PM

$NNVC trend lines squeezing here, looking for a bullish move next week.

0 · Reply

Stockprofiler Sep. 12 at 3:35 PM

$NNVC Time to cover for Shorts. #Shortsqueeze

0 · Reply

Stockprofiler Sep. 12 at 3:32 PM

$NNVC in Recent press - #FDA NanoViricides (NYSE:NNVC) reported that its broad-spectrum antiviral drug NV-387, which has completed Phase I clinical trials, could help reduce metastatic cancer resurgence triggered by viral infections. The drug's unique ability to reduce inflammation, particularly IL-6 cytokine levels, may prevent the reactivation of dormant cancer cells during viral infections. https://www.nasdaq.com/press-release/nanoviricides-discusses-multi-billion-dollar-potential-its-broad-spectrum-drug-nv-387

0 · Reply

Market Cap	23.30M
Revenue (ttm)	0.00
Net Income (ttm)	-8.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	85,100
Avg Vol	201,516
Day's Range	N/A - N/A
Shares Out	16.07M
Stochastic %K	67%
Beta	1.15
Analysts	Strong Sell
Price Target	$6.50